A new study examining real-world hospital data reveals early indicators of who is most likely to benefit from Cobenfy, the ...
WEST HARTFORD, CT, UNITED STATES, April 27, 2023/ EINPresswire.com / -- The Journal of Clinical Psychopharmacology and CMEology, leaders in continuing education for health care professionals, have ...
This post was written by Eugene Rubin, MD, Ph.D., and Charles Zorumski, MD. Schizophrenia is a severe, chronic disorder characterized by "positive" symptoms such as hallucinations, delusions (fixed, ...
Please provide your email address to receive an email when new articles are posted on . The EMERGENT 2 and EMERGENT-3 trials included 508 adults with schizophrenia and acute psychosis. KarXT ...
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia, which ...
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric ...
Future therapies for the treatment of schizophrenia are explored by a panel of key opinion leaders. John J. Miller, MD: The pipeline as it’s evolving has come full circle; when we began, I talked ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback